New frontiers in the management of type 2 diabetes

Indian Journal of Medical Research

Volumn 125, Issue 3, 2007, Pages 275-296

  Mudaliar, Sunder ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Glucose lowering agents; Non invasive therapy; Recent advances; Treatment; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALBUGON; ANTIDIABETIC AGENT; AT 1391; CJC 1131; EXENDIN 4; FIBRIC ACID DERIVATIVE; GASTROINTESTINAL HORMONE; GLIMEPIRIDE; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; MURAGLITAZAR; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; PROPELLANT; RECOMBINANT HUMAN INSULIN; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ADJUVANT THERAPY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PACKAGING; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL SYMPTOM; HEALTH PROGRAM; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INDIA; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULINOMA; LIFESTYLE; LIPID BLOOD LEVEL; MEDICAL RESEARCH; METERED DOSE INHALER; MONITOR; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT EDUCATION; PERIPHERAL EDEMA; POWDER INHALER; REVIEW; RISK MANAGEMENT; SENSOR; SIDE EFFECT; STROKE; TRANSDERMAL PATCH; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; THIAZOLIDINEDIONES;

EID: 34249288293     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
2. Harris MI. Summary. In: Harris MI, Courie CC, Stern MP, Boyko EJ, Reiber GE, Bennet PH, editors. Diabetes in America, 2nd ed. Washington, DC: US Department of Health and Human Services, National Institute of Health, DHHS publication no.(NIH) 95-1468; 1995.
3. DeFronzo RA: Lilly, Lecture 1987: The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37: 667-87.
4. Pratley RE. Weyer C: The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001; 44: 929-45.
5. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
6. Fagan TC, Deedwania PC. The cardiovascular dysmetabolic syndrome. Am J Med 1998; 105: 77S-82.
7. http://www.idf.org/home/index.cfm (accessed March 13, 2006).
8. Standards of Medical Care in Diabetes - 2006 American Diabetes Association. Diabetes Care 2006; 29: S4-42.
9. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-72.
10. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67.
11. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
13. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
14. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
15. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
16. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
17. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with life style intervention or metformin. N Engl J Med 2002; 346: 393-403.
18. Krolewski AS, Warram JH, Valsania P, Martin BC, Laffel LM. Christlieb AR. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991; 90: 56S-61.
19. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
20. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001; 322: 1389-93.
21. Mudaliar S, Henry RR. PPAR agonists in health and disease: a pathophysiologic and clinical overview. Curr Opin Endocrinol Diabetes 2002; 9: 285-302.
22. Kunhiraman BP, Jawa A, Fonseca VA. Potential cardiovascular benefits of insulin sensitizers. Endocrinol Metab Clin North Am 2005; 34: 117-35.
23. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Bennedetti M, Moules IK, et al. The PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive,Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
24. Fonseca V, Jawa A, Asnani S. The PROactive Study- The glass is half full. J Clin Endocrinol Metab 2006; 91: 25-7.
25. Rizza R, Henry R, Kahn R. Commentary on the Results and Clinical Implications of the PROactive Study. Diabetes Care 2005; 28: 2965-7.
26. http://www.nih.gov/news/pr/feb2003/nhlbi-20.htm, accessed on March 13, 2006.
27. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005; 48: 1726-35.
28. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294: 2581-6.
29. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006; 29: 435-49.
30. Gallwitz B. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass. Diabetes Technol Ther 2005; 7: 651-7.
31. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regulatory Peptides 2005; 128: 135-48.
32. Ruggles JA. Kelemen D. Baron A. Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration. Endocrinol Metab Clin North Am 2004; 33: 239-52.
33. Defronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100.
34. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Finemann MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-91.
35. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD for the Exenatide-113 Clinical Study Group. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-635.
36. http://www.amylin.com/pipeline/exenatidelar.cfm (accessed March 13, 2006).
37. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1340 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-42.
38. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide dose Response Study Group. Effects of liraglutide (NN2211), a long acting GLP-1 analogue, on glycaemic control and body weight in subjects with type 2 diabetes. Diabet Med 2005; 22: 1016-23.
39. Holst JJ. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 2004; 9: 155-66.
40. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-80.
41. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformintreated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-40.
42. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-88.
43. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004; 53 (Suppl 3): S233-8.
44. Young AA. Amylin's physiology and its role in diabetes. Carr Opin Endocrinol Diabetes 1997; 4: 282-90.
45. Kruger DF, Gloster MA. Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs 2004; 64: 1419-32.
46. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26: 784-90.
47. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005; 143: 549-58.
48. Mollema ED, Snoek FJ, Heine RJ, van der Ploeg HM. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med 2001; 18: 671-4.
49. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999; 46: 239-46.
50. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28: 1077-82.
51. Quattrin T, Bélanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-7.
52. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-62.
53. McMahon GT, Arky RA. Inhaled insulin for diabetes mellitus. N Engl J Med 2007; 356: 497-502.
54. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43: 781-801.
55. http://www.fda.gov/bbs/topics/news/2OO6/NEW01304.html (accessed March 13, 2006).
56. Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004; 27: 162-7.
57. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health-System Pharmacy 2005; 62: 1359-64.
58. Rave KM, Nosek L, de la Pena A, Seger M, Ernest CS 2nd, Heinemann L, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005; 28: 2400-5.
59. Pfutzner A, Forst T. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv 2005; 2: 1097-106.
60. http://www.generex.com (accessed March 13, 2006).
61. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Technol Ther 2004; 6: 1-8.
62. http://www.nobex.com (accessed March 13, 2006).
63. Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 2003; 26: 421-6.
64. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the Eligen technology: mechanistic studies. Curr Drug Deliv 2005; 2: 191-7.
65. http://www.alteatherapeutics.com/ (accessed March 13, 2006).
66. http://www.dermisonics.com/ (accessed March 13, 2006).
67. http://www.starbridgesystems.co.uk/ (accessed March 13, 2006).
68. Catargi B. Current status and future of implantable insulin pumps for the treatment of diabetes. Expert Rev Med Devices 2004; 1: 181-5.
69. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997; 20: 1847-53.
70. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999; 46: 183-90.
71. Skyler JS. The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. Diabetes Technol Ther 2000; 2 (Suppl 1): S7-12.
72. Klonoff DC. A review of continuous glucose monitoring technology. Diabetes Technol Ther 2005; 7: 770-5.
73. Garg SK, Hoff HK, Chase HP. The role of continuous glucose sensors in diabetes care. Endocrinol Metab Clin North Am 2004; 33: 163-73.
74. Chase HP, Roberts MD, Wightman C, Klingensmith G. Garg SK, Van Wyhe M, et al. Use of the Gluco Watch biographer in children with type 1 diabetes. Pediatrics 2003; 111: 790-4.
75. Chase HP, Beck R, Tamborlane W, Buckingham B, Mauras N, Tsalikian E, et al. A randomized multicenter trial comparing the Gluco Watch Biographer with standard glucose monitoring in children with type 1 diabetes. Diabetes Care 2005; 28: 1101-6.
76. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care 2004; 27: 734-8.
77. Pfutzner A, Caduff A, Larbig M, Schrepfer T, Forst T. Impact of posture and fixation technique on impedance spectroscopy used for continuous and noninvasive glucose monitoring. Diabetes Technol Ther 2004; 6: 435-41.
78. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, et al. Improvement in glycemic excursions with a transcutaneous, Real-time continuous glucose sensor: A randomized controlled trial. Diabetes Care 2006; 29: 4-50.
79. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-44.
80. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
81. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
82. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-97.
83. The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28: 2472-9.
84. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-7.
85. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. The Diabetes Prevention Program Research Group. Diabetes 2005; 54: 1150-6.
86. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
87. Padwal R, Majumdar SR, Johnson JA, Varney J, Mcalister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005; 28: 736-44.
88. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004; 27: 247-55.
89. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-8.
90. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363 757-67.
91. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care 2003; 26: 2713-21.
92. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
93. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, et al. Peroxisome proliferators-activated receptor ligand Bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004; 109: 2197-202.
94. Kanaya AM, Herrington D, Vittinghoff E Lin F, Grady D, Bittner V, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study. Ann Intern Med 1992; 138: 1-9.
95. Chiasson JL, Brindisi MC, Rabasa-Lhoret R. The prevention of type 2 diabetes: what is the evidence? Minerva Endocrinol 2005; 30: 179-91.
96. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47: 1519-27.
97. Venkat Narayan KM. The diabetes pandemic: Looking for the silver lining. Clin Diabetes 2005; 23: 51-2.